Olanzapine: Side Effects, Uses & Monitoring
1.1 SchizophreniaOral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults.
- Data source
- FDA labeling via NIH DailyMed (label 66ef201f…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Somnolence | 35% |
| Dry mouth | 22% |
| Dizziness | 18% |
| Asthenia | 15% |
| Accidental injury | 12% |
| Insomnia | 12% |
| Constipation | 11% |
| Dyspepsia | 11% |
| Personality disordera | 8% |
| Rhinitis | 7% |
| Speech disorder | 7% |
| Increased appetite | 6% |
| Tremor | 6% |
| Fever | 6% |
| Abnormal gait | 6% |
| Cough increased | 6% |
| Increased salivation | 6% |
| Back pain | 5% |
| Ecchymosis | 5% |
| Weight gain | 5% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
1.1 SchizophreniaOral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies (14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I ManiaZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to t…
Conditions associated with Olanzapine in labeling
Frequently Asked Questions
What is Olanzapine used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Olanzapine?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Olanzapine. Individual risk varies.
Does Olanzapine require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Olanzapine.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.